Clinical Mass Spectrometry Market – Insights
Clinical mass spectrometry is widely accepted in research, specialized clinical laboratories, and its adoption is significantly increasing in routine laboratories. The combination of mass spectrometry with gas chromatography (GC) or liquid chromatography (LC) has contributed to the rapid expansion of this technology. Mass spectrometry (MS) has application in many clinical areas such as therapeutic drug monitoring, drugs of abuse, and clinical toxicology.
Clinical mass spectrometry serves as a quantitative and qualitative analytical tool for assessment of complex mixtures in all phases of drug development such as identification of the lead compound and their conformational details. Clinical laboratories manage a large number of samples through total automation or analyzer automation, which is offered by clinical mass spectrometers such as matrix assisted laser desorption/ionization (MALDI-TOF). These automated platforms assist in effective processing of increasingly large workloads. Thus, clinical laboratories are among the largest end users in this market.
Moreover, advancements in clinical mass spectrometry has facilitated measuring and distinguishing of separate contributions of molecules such as thyroid hormones and 25-hydroxyl vitamins D2 and D3. Application of translational research in mass spectrometry has helped in detecting blood-based biomarkers, endogenous metabolites, tumor markers, and new disease biomarkers. These advancements are expected to fuel demand for clinical mass spectrometry devices.
The global clinical mass spectrometry market size is estimated to be valued at US$ 697.2 million in 2019, and is expected to exhibit a CAGR of 5.5% over the forecast period (2019 – 2027).
Global Clinical Mass Spectrometry Market Share (%) Analysis, By Product Type, 2019
Source: Coherent Market Insights Analysis (2019)
Increasing demand for automation in diagnostic techniques is expected to drive growth of the clinical mass spectrometry market
Mass spectrometry helps with a variety of diagnostic analysis, and research in functional genomics, metabolomics, and proteomics. These factors are driving the need for development of a cost-effective platform for sample analysis. As a result, manufacturers are focused on product development and innovations to address the demand for automated diagnostic tools. For instance, in 2017, Thermo Fisher Scientific Inc. launched Scientific Cascadion SM Clinical Analyzer at a EuroMedLab event held in Athens, Greece, to use the clinical analyzers with the selectivity and sensitivity of liquid chromatography-tandem mass spectrometry.
Automated laboratory systems provide several high-end functionalities such as MassEXTEND primer extension and nano liter dispensing of samples on to spectroCHIPS, and data analysis by using pre-loaded workstations. Ease of management, quick results, and less complex functionality by these facilities is associated with low cost. Apart from cost-effectiveness, improved quality assays, simplicity for use, automation, data reliability, increased sensitivity, reduced cross-reactivity & non-specific binding, and low downtime are the advantages offered by mass spectrometers over conventional immunoassays.
Clinical Mass Spectrometry Market – Restraints
The capital investment associated with installation and maintenance of these devices is expected to restrain growth of the global market. Mass spectrometers are largely unaffordable for small diagnostic clinics and laboratories especially in emerging economies. Moreover, mass spectrometry is labor intensive and requires skilled workforce to operate the devices. Shortage of skilled operators is expected to hamper the market growth.
Clinical Mass Spectrometry Market - Regional Insights
On the basis of region, the global clinical mass spectrometry market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold the largest share in the clinical mass spectrometry market over the forecast period, owing to Research and development activities, coupled with governmental support are factors driving growth of the North America market. For instance, the Federation of analytical Chemistry and Spectrometry Societies, and American Society for Mass Spectrometry, which was formed in 1969, with over 7,500 scientists working together on advancing clinical application of mass spectrometry and allied topics in academic, industrial, and governmental fields. This has created a strong research base in North America which is contributing to the growth of the clinical mass spectrometry market in the region.
Global Clinical Mass Spectrometry Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027
Source: Coherent Market Insights Analysis (2019)
Clinical Mass Spectrometry Market - Competitive Landscape
Major players operating in the global clinical mass spectrometry market include Bruker Corporation, Kore Technology Limited, Bergman Messgerate Entwicklung KG, Mass Spectrometry Instruments (MSI), Thermo Fisher Scientific Inc., Agilent Technologies, and Danaher Corporations.